Q2 2026 13F · SEC CIK 1131399
GSK plc
CorporationFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $602.2M
- Reported positions
- 13
- Holdings vs S&P 500, 3 yrs
- —
- Average holding period
- 3 qtrs
GSK plc is a corporation that reported 13 positions worth $602.2M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Crispr Therapeutics AG (CRSP, 29.2%), Wave Life Sciences Ltd (WVE, 17.6%), Vir Biotechnology Inc (VIR, 14.5%).
GSK plc holdings all 13 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| CRSPCrispr Therapeutics AG | 29.2% | +0.0% | $175.7M |
| WVEWave Life Sciences Ltd | 17.6% | +0.0% | $106.0M |
| VIRVir Biotechnology Inc | 14.5% | +0.0% | $87.1M |
| BNTXBiontech SE | 13.7% | +0.0% | $82.8M |
| IDYAIdeaya Biosciences Inc | 8.3% | +0.0% | $49.7M |
| CYTKCytokinetics | 4.8% | +0.0% | $29.0M |
| LYELLyell Immunopharma Inc | 3.5% | +0.0% | $21.3M |
| SPROSpero Therapeutics Inc | 3.4% | +0.0% | $20.3M |
| NKTXNkarta Inc | 1.5% | +0.0% | $8.9M |
| FULCFulcrum Therapeutics Inc | 1.1% | +0.0% | $6.5M |
| BCYCBicycle Therapeutics PLC | 1.1% | +0.0% | $6.5M |
| CVRXCvrx Inc | 0.9% | +0.0% | $5.2M |
| RGNXRegenxbio Inc | 0.5% | +0.0% | $3.3M |
What GSK plc bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
No position grew by more than 5%.
Reduced
No position shrank by more than 5%.
Sold out
Nothing sold out.
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- —
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $602.2M | 13 |
| Q1 2026 | $599.2M | 13 |
| Q4 2025 | $799.0M | 15 |
Questions about GSK plc's portfolio
What stocks does GSK plc own?
GSK plc's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 13 positions worth $602.2M. The largest are Crispr Therapeutics AG (CRSP) at 29.2%, Wave Life Sciences Ltd (WVE) at 17.6%, Vir Biotechnology Inc (VIR) at 14.5%, Biontech SE (BNTX) at 13.7% and Ideaya Biosciences Inc (IDYA) at 8.3%.
What did GSK plc buy last quarter?
GSK plc opened no new positions and grew none by more than 5% among its largest holdings in Q2 2026.
What did GSK plc sell last quarter?
GSK plc sold out of nothing and cut no large position by more than 5% in Q2 2026.
When is GSK plc's next 13F filing due?
13F filings are due 45 days after each quarter ends. GSK plc's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.